News articles about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albany Molecular Research earned a news impact score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1381582474222 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Albany Molecular Research, Inc. (NASDAQ:AMRI) Files An 8-K Submission of Matters to a Vote of Security Holders (4-traders.com)
- AMRI shareholders approve sale of company (finance.yahoo.com)
- S&P Global : Control4 Set to Join S&P SmallCap 600 (4-traders.com)
- Albany Molecular Research, Inc. (AMRI) Upgraded to “Hold” at BidaskClub (americanbankingnews.com)
Albany Molecular Research (AMRI) traded down 0.05% during midday trading on Friday, reaching $21.73. 684,509 shares of the company’s stock traded hands. The firm’s 50-day moving average is $21.71 and its 200 day moving average is $18.21. The firm’s market cap is $905.40 million. Albany Molecular Research has a 52-week low of $13.01 and a 52-week high of $22.17.
Several research firms have commented on AMRI. BidaskClub upgraded shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. J P Morgan Chase & Co lowered shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. William Blair lowered shares of Albany Molecular Research from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 6th. First Analysis lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. Finally, Morgan Stanley lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a research note on Thursday, May 11th. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating, Albany Molecular Research has an average rating of “Hold” and an average price target of $18.00.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with our FREE daily email newsletter.